Cargando…

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

Background: Life expectancy for patients with malignant tumors has been significantly improved since the presence of the programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) inhibitors in 2014, but they impose heavy financial burdens for patients, the healthcare system...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Shen, Huang, Yaping, Dong, Liangliang, Li, Meiyue, Wang, Yahong, Gu, Dian, Wu, Wei, Nian, Dongni, Luo, Shaohong, Huang, Xiaoting, Xu, Xiongwei, Weng, Xiuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995671/ https://www.ncbi.nlm.nih.gov/pubmed/36909180 http://dx.doi.org/10.3389/fphar.2023.1114304

Ejemplares similares

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
por: Weng, Xiuhua, et al.
Publicado: (2020)

Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
por: Huang, Xiaojia, et al.
Publicado: (2023)

Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS
por: Jiang, Qian, et al.
Publicado: (2020)

The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS
por: Ha, Hyerim, et al.
Publicado: (2022)

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe
por: Pavlidis, Nicholas, et al.
Publicado: (2016)

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
por: Dittrich, Christian, et al.
Publicado: (2016)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
por: Cufer, Tanja, et al.
Publicado: (2023)

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016
por: Dittrich, C., et al.
Publicado: (2016)

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
por: Everest, Louis, et al.
Publicado: (2019)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey
por: Cufer, T., et al.
Publicado: (2021)

Aktueller Stand zu „liquid biopsy“ und Diagnostik – Beiträge vom ASCO und ESMO 2022
por: Blaurock, Markus, et al.
Publicado: (2023)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
por: Li, Meiyue, et al.
Publicado: (2021)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials
por: Zhao, Qiuling, et al.
Publicado: (2018)

Enhancing the Value of the ASCO Value Framework
por: Morton, Alec, et al.
Publicado: (2018)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy
por: Lin, Mao, et al.
Publicado: (2022)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
por: Li, Zhiyang, et al.
Publicado: (2021)

Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
por: Pichler, M., et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

PD‐1/PD‐L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
por: Zhao, Rui, et al.
Publicado: (2019)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
por: Xue, Gang, et al.
Publicado: (2019)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
por: Tomlins, Scott A., et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)
por: Du, Jiangfeng, et al.
Publicado: (2018)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8d3c62817jvdass1a0v45f35i9